Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	2.00B
Revenue (ttm)	221.00M
Net Income (ttm)	-69.80M
Shares Out	16.55M
EPS (ttm)	-4.24
PE Ratio	n/a
Forward PE	226.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,278
Average Volume	27,469
Open	119.20
Previous Close	119.00
Day's Range	118.00 - 122.00
52-Week Range	83.30 - 145.00
Beta	0.78
RSI	66.75
Earnings Date	Jul 22, 2025

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 121
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.